medwireNews: The overall survival (OS) advantage offered by the use of durvalumab alongside first-line chemotherapy in people with extensive-stage small-cell lung cancer (SCLC) is sustained over time, suggests the 3-year follow-up of the CASPIAN study.
Almost three times as many patients given chemoimmunotherapy were alive at 3 years as those given chemotherapy alone, investigator Luis Paz-Ares (Hospital Universitario 12 de Octubre, Madrid, Spain) told the audience at the ESMO Congress 2021.
Specifically, the OS rate was 17.6% for the 268 patients who received four courses of durvalumab 1500 mg alongside etoposide–platinum every 3 weeks and 5.8% among the 269 who received up to six cycles of chemotherapy alone.
The hazard ratio for death was a significant 0.71 in favor of adding the PD-L1 inhibitor in this analysis conducted at a median follow-up of 39.4 months, mirroring the primary findings previously reported by medwireNews.
Moreover, “the adverse event profile continued to be quite favorable,” said the presenter, and he concluded: “Taken together, these data further establish the combination of durvalumab and etoposide–platinum as a standard of care for this patient population.”
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group